Osimertinib/osimertinib drug introduction

Osimertinib/Osimertinib (Osimertinib), also known as mesylateOsimertinib/Osimertinib tablets (Osimertinib Mesylate Tablets), is an oral targeted therapy drug, mainly used to treat EGFR (epidermal growth factor receptor) gene mutation-positive advanced non-small cell lung cancer (NSCLC).

Osimertinib/Osimertinib belongs to the third generation of EGFRtyrosine kinase inhibitors. Compared with other EGFR inhibitors, it has higher Selective, specifically targeting EGFR sensitive mutations (such as Del19 and L858R mutations) and EGFR T790M mutation, this mutation is one of the common mechanisms of resistance to other EGFR inhibitors.

The main mechanism of action is to interfere with the growth, proliferation and survival of tumor cells by inhibiting the EGFR signaling pathway, thereby inhibiting the development and metastasis of tumors. Compared with traditional chemotherapy drugs, Osimertinib/Osimertinib has higher therapeutic effect and fewer toxic side effects, which can effectively prolong the survival time of patients and improve the quality of life.

Osimertinib/The pharmaceutical dosage form of Osimertinib is generally an oral tablet, which is convenient for patients to treat at home. Usually, patients take oral osimertinib /osimertinib tablets every day and use them according to the doctor's instructions and dosage to ensure the safety and effectiveness of the treatment.

Overall,osimertinib/osimertinibAs a targeted therapy drug, it has significant therapeutic effect and less toxic side effects for advanced non-small cell lung cancer with positive EGFR gene mutation. It provides patients with an effective treatment option and improves the survival rate and quality of life of patients with advanced lung cancer.